BRIEF COMMUNICATION

Role of plasmapheresis in the treatment of severe pruritus in pregnant patients with primary biliary cirrhosis: Case reports

Alallam Alallam MD, David Barth MD, E Jenny Heathcote MD

A Alallam, D Barth, EJ Heathcote. Role of plasmapheresis in the treatment of severe pruritus in pregnant patients with primary biliary cirrhosis: Case reports. Can J Gastroenterol 2008;22(5):505-507.

BACKGROUND: Primary biliary cirrhosis (PBC) may be associated with pruritus and, when present, may be accentuated during pregnancy. Several therapeutic modalities have been used to control itching caused by cholestasis, with variable responses. Drug therapies are ill-advised, particularly in early pregnancy. Plasmapheresis has been successful in controlling pruritus in patients with cholestasis. The use of plasmapheresis to alleviate severe life-threatening pruritus during pregnancy is reported in two patients with PBC.

CASE PRESENTATIONS: Two patients with PBC presented during their second trimester of pregnancy with severe pruritus that did not respond to the anion exchange resin cholestyramine. Their symptoms were disabling to the point that one patient had suicidal ideation. Given the severity of their symptoms, multiple sessions of plasmapheresis were instituted with good control of pruritus. Both patients tolerated the procedure well and delivered healthy babies.

CONCLUSION: Plasmapheresis is a relatively safe and rapidly effective treatment for severe pruritus during pregnancy in patients with PBC.

Key Words: PBC; Plasmapheresis; Pregnancy; Primary biliary cirrhosis; Pruritus

Rôle de la plasmaphérèse dans le traitement du prurit intense chez des patientes enceintes souffrant de cirrhose biliaire primaire : Rapports de cas

HISTORIQUE : La cirrhose biliaire primaire (CBP) peut être associée au prurit qui, le cas échéant, se trouve accentué durant la grossesse. Plusieurs modalités thérapeutiques ont été utilisées pour maîtriser les démangeaisons causées par la cholestase avec des résultats variables. Les traitements médicaux sont à déconseiller, surtout en début de grossesse. La plasmaphérèse a permis de corriger le prurit chez les patientes présentant une cholestase. Les auteurs présentent ici deux rapports de cas de patientes atteintes de CBP chez qui la plasmaphérèse a été utilisée avec succès pour soulager un prurit gravissime durant la grossesse.

PRÉSENTATION DE CAS : Deux patientes atteintes de CBP ont consulté au cours de leur second trimestre de grossesse pour un prurit intense qui ne répondait pas à la cholestyramine, une résine échangeuse d’anions. Leurs symptômes étaient invalidants au point où une patiente a songé au suicide. Compte tenu de la gravité de leurs symptômes, plusieurs séances de plasmaphérèse ont été instaurées et ont permis de corriger le prurit. Les deux patientes ont bien toléré l’intervention et ont donné naissance à des bébés en bonne santé.

CONCLUSION : La plasmaphérèse est une intervention relativement sûre et rapidement efficace pour le prurit sévère durant la grossesse chez des patientes atteintes de CBP.

Primary biliary cirrhosis (PBC) is a variably progressive autoimmune disease of the liver that primarily affects women (1). Pruritus is the second most common symptom (after fatigue) of PBC, occurring in 19% of patients (2). It may be quite severe and occasionally is refractory to medical treatment. Pruritus occurring de novo during pregnancy may be the first presenting symptom of PBC, brought to the fore by the cholestatic effect of estrogen. But unless a diagnosis of PBC is made before the patient becomes pregnant, it may be mistaken for pruritus related to idiopathic cholestasis of pregnancy (3). However, the pattern of liver enzymes in the latter is typically hepatic (ie, aspartate aminotransferase [AST], alanine aminotransferase [ALT]) and gamma-glutamyl transferase [GGT] levels are often normal, with minimal elevation in alkaline phosphatase [ALP] levels). The pathogenesis of pruritus secondary to cholestasis remains uncertain, but the role of bile acid accumulation in tissues may be a factor (4). Others have suggested that the high level of endogenous opioids that can be detected in patients with PBC may also be responsible for pruritus (5).

Cholestyramine has been recommended as the first-line therapy for pruritus of cholestasis (6). Rifampin is also effective in controlling pruritus in 77% of patients, at least over the short term, according to a recent meta-analysis (7). The opioid antagonists, naloxone (8) and naltrexone (9), have also been shown to alleviate pruritus of cholestasis. However, their use may be accompanied by symptoms typical of opioid ‘withdrawal’ and, when given over the long term, may be associated with chronic pain syndrome (10). Sertraline has been shown, in a small, randomized, placebo-controlled trial (11), to reduce the pruritus of cholestasis. Ursodeoxycholic acid, which is the standard of care for PBC (6), has not brought relief of pruritus in patients with PBC (12), in contrast to the benefits seen when using this agent to treat intrahepatic cholestasis of
pregnancy (13). Clinical experience suggests that the prurito-
gen of cholestasis is present in bile and in blood, because bil-
ary diversion (14,15), extracorporeal albumin dialysis (16,17)
and plasmapheresis (18,19) effectively alleviate pruritus of
cholestasis.

We report our experience of safely treating severe pruritus
with plasmapheresis in two pregnant women with PBC. To our
knowledge, the present paper is the first to report the use of
plasmapheresis to treat severe pruritus during pregnancy in
patients with PBC.

**CASE PRESENTATIONS**

**Patient 1**
A 33-year-old pregnant woman with biopsy-proven PBC is
described. She first presented at 28 years of age with pruritus
and was found to have elevated serum bilirubin and ALP lev-
els, and tested antimitochondrial antibody-positive. Her liver
profile was: ALT 143 U/L (normal level less than 40 U/L);
AST 98 U/L (normal level less than 40 U/L); ALP 690 U/L
(normal level less than 112 U/L); total bilirubin 36 μmol/L
(normal level less than 23 μmol/L); albumin 47 g/L (normal
level greater than 35 g/L); and an international normalized
ratio (INR) of 0.97. An ultrasound of her liver was normal.
Her liver biopsy showed stage I-II PBC. She was noted to
have unconjugated hyperbilirubinemia (Gilbert's syndrome).
She was started on ursodeoxycholic acid (UDCA) 1 g/day
with dinner, and cholestyramine was prescribed to be taken
before and after breakfast to treat her pruritus. The latter
treatment had no significant effect. Her prescription was
changed to rifampin 150 mg twice per day, which led to bet-
ter control of her pruritus. One year later, the patient planned
to get pregnant; UDCA and rifampin were stopped per
patient’s request to avoid any potential drug effects on the
fetus. Over the following four years, she took UDCA twice
for intermittent periods when she was not planning to con-
ceive. Her pruritus was manageable without medication. She
succeeded in becoming pregnant at 33 years of age. The
patient developed significant pruritus at 12 weeks gestation.
The only medication she was taking was a multivitamin. At
that time, her liver profile was: ALT 137 U/L; AST 81 U/L;
ALP 301 U/L; GGT 151 U/L; total bilirubin 28 μmol/L; albumin 36 g/L;
and an INR of 0.92. She was restarted on cholestyramine 4 g twice
per day before and after breakfast, and UDCA 1 g daily with din-
er. However, by the 31st week of gestation, the patient’s pru-
ritis was so severe that it interfered with her sleep and ability
to care for her family. Her cholestyramine was increased to 4 g
times per day but this was unhelpful. Once referred to the
liver clinic at Toronto Western Hospital, other oral agents
usually used in the treatment of pruritus due to cholestasis
(i.e., rifampin and opioid antagonists) were declined by the
patient, who was concerned about any potential effect on the
fetus. The patient underwent plasmapheresis to manage her
pruritus. This was performed on two consecutive days that
week, with significant alleviation of her pruritus. Thereafter,
plasmapheresis was repeated every 10 days until delivery, with
a total of six exchanges. Each exchange consisted of one
plasma volume with 5% albumin as replacement fluid. No
complications were reported during the exchanges. The
patient delivered a 3.2 kg boy after induction of labour at
38 weeks gestation. The patient continued to have pruritus
after delivery, which supported the diagnosis of PBC. Five
months later, a liver biopsy showed stage I-II PBC with 90% loss of bile ducts. The baby continues to do well.

**DISCUSSION**
Plasmapheresis is a rapid-acting, effective rescue procedure
that may be used to gain immediate control of pruritus due to
cholestasis. Plasmapheresis is an extracorporeal procedure that
can remove large molecular weight substances from the
plasma. It is generally safe and well tolerated, and can be used
safely in pregnant women, although rare complications of
hypotension and citrate reaction may occur. The exact mech-
anism of how plasmapheresis decreases pruritus is unknown.

To our knowledge, the present report describes the first
time that plasmapheresis has been used to treat pruritus in
patients with PBC during pregnancy. In the first case, the
severity of pruritus was life-threatening. Plasmapheresis was a
very useful emergency tool, which controlled the patient’s
symptoms almost immediately until other therapies (i.e,
rifampin and ultraviolet B light) were introduced and given
time to exert their beneficial effect. The second patient, who
had been given cholestyramine without benefit, had pruritus
that was sufficiently severe to interfere with her daily life and
her ability to look after her three children. Plasmapheresis
was performed because she declined trying other oral agents,
and it controlled her symptoms quickly. This benefit was
maintained by repeated plasmapheresis throughout the rest of
her pregnancy. No deterioration in liver or fetal function was
noted in either case after the introduction of plasmapheresis.
treatment. The first patient experienced premature labour at 31 weeks gestation. It is unlikely that this was due to the plasmapheresis procedure, because it occurred eight weeks after her last session. However, it may have been prompted by her chronic cholestasis. The second patient had a term delivery despite receiving plasma exchange on an intermittent basis until the end of her pregnancy. Both patients had babies who have thrived.

Estrogens are known to provoke cholestasis. Exogenous estrogens (eg, oral contraceptives) are associated with pruritus and jaundice in women who are prone to cholestasis of pregnancy (20,21). However, Poupon et al (22) reported a follow-up study of nine pregnancies in six patients with PBC. These patients were all taking UDCA and none had pruritus before becoming pregnant. All patients remained without pruritus during their entire pregnancy. The present paper reports two patients with PBC (both of whom had experienced pruritus before their pregnancy) whose pruritus worsened during pregnancy. It is possible that severe pruritus during pregnancy in women with PBC is more likely to happen in those who have pruritus before pregnancy. Their symptoms presumably are aggravated by the high estrogen levels present during pregnancy. Plasmapheresis is an expensive and limited resource. It should be reserved for cases of pruritus that are incapacitating and/or when oral agents have failed.

**CONCLUSION**

Plasmapheresis is a relatively safe and rapidly effective treatment for severe pruritus during pregnancy in patients with PBC.

**REFERENCES**

1. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. New Engl J Med 2005;353:1261-73.
2. Witt-Sullivan H, Heathcote J, Cauch K, et al. The demography of primary biliary cirrhosis in Ontario, Canada. Hepatology 1990;12:98-105.
3. Leuschner U. Primary biliary cirrhosis – presentation and diagnosis. Clin Liver Dis 2003;7:741-58.
4. Szalay F. Treatment of primary biliary cirrhosis. J Physiol Paris 2001;95:407-12.
5. Thornton JR, Losowsky MS. Opioid peptides and primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 2000;31:1005-13.
6. Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis. J Hepatol 2005;42:418-9.
7. Bergasa NV, Alling DW, Talbot TL, et al. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med 1995;123:161-7.
8. Mameen-Ghanaei F, Taheri A, Froustani H, et al. Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol 2006;12:1125-8.
9. Yii WC, Prince MI, Hudson M, Day CP, James OF, Jones DE. Pain as a complication of use of opiate antagonists for symptom control in cholestasis. Gastroenterology 2003;125:591-6.
10. Browning J, Combes B, Mayo MJ. Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 2003;98:2736-41.
11. Heathcote EJ, Cauch-Dudek K, Walker V, et al. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994;19:1149-56.
12. Pares A, Civera L, Salmeron JM, et al. Extracorporeal albumin dialysis: A procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. J Gastroenterol Hepatol 1997;12:1105-10.
13. Palma J, Reyes H, Ribaltita J, et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: A randomized, double-blind study controlled with placebo. J Hepatol 1997;27:1022-8.
14. Ng VL, Ryckman FC, Porta G, et al. Long-term outcome after partial external biliary diversion for intractable pruritus in patients with intrahepatic cholestasis. J Pediatr Gastroenterol Nutr 2000;30:152-6.
15. Beuers U, Gerken G, Puls T. Biliary drainage transiently relieves intractable pruritus in primary biliary cirrhosis. Hepatology 2006;44:280-1.
16. Acevedo Ribó M, Moreno Planas JM, Sanz Moreno C, et al. Therapy of intractable pruritus with MARS. Transplant Proc 2005;37:1480-1.
17. Reyes H, Simon FR. Intrahepatic cholestasis of pregnancy: The role of plasmapheresis in primary biliary cirrhosis. Gut 1985;26:291-4.
18. Warren JE, Blaylock RC, Silver RM. Plasmapheresis for the treatment of intrahepatic cholestasis of pregnancy refractory to medical treatment. Am J Obstet Gynecol 2005;192:2088-9.
19. Reyes H, Simon FR. Intrahepatic cholestasis of pregnancy: An estrogen-related disease. Semin Liver Dis 1993;13:289-301.
20. Kreek MJ, Weser E, Leissinger MH, Jeffries GH. Idiopathic cholestasis of pregnancy. The response to challenge with synthetic estrogen, ethinyl estradiol. N Engl J Med 1967;277:1391-5.
21. Poupon R, Chretien Y, Chazouilleres O, Poupon RE. Pregnancy in women with ursodeoxycholic acid-treated primary biliary cirrhosis. J Hepatol 2005;42:418-9.
